Forty Seven Stock

Clinical-stage immuno-oncology company

Sign up today and learn more about Forty Seven Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About Forty Seven Stock

With a passion for pioneering breakthrough solutions, we are committed to the advancement of immuno-oncology through the engagement of new and complementary phagocytic pathways that enhance anti-tumor efficacy and selectivity.

Investors

Funding History

February 2016$75.0M

Management

Cofounder

Irving Weissman

Press

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

Logo